NeuBase Therapeutics Inc. (NASDAQ:NBSE) and BioTime Inc. (:), both competing one another are Biotechnology companies. We will compare their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for NeuBase Therapeutics Inc. and BioTime Inc.

Profitability

Table 2 shows us NeuBase Therapeutics Inc. and BioTime Inc.s return on equity, net margins and return on assets.

Volatility and Risk

A 0.89 beta indicates that NeuBase Therapeutics Inc. is 11.00% less volatile compared to Standard & Poors 500. Competitively, BioTime Inc.s 181.00% volatility makes it more volatile than Standard & Poors 500, because of the 2.81 beta.

Liquidity

The Current Ratio of NeuBase Therapeutics Inc. is 3.7 while its Quick Ratio stands at 3.7. The Current Ratio of rival BioTime Inc. is 3.5 and its Quick Ratio is has 3.5. NeuBase Therapeutics Inc. is better equipped to clear short and long-term obligations than BioTime Inc.

Analyst Ratings

NeuBase Therapeutics Inc. and BioTime Inc. Ratings and Recommendations are available in the next table.

The consensus target price of NeuBase Therapeutics Inc. is $14.5, with potential upside of 184.31%.

Institutional and Insider Ownership

The shares of both NeuBase Therapeutics Inc. and BioTime Inc. are owned by institutional investors at 3.1% and 43.7% respectively. Competitively, 3.9% are BioTime Inc.s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year NeuBase Therapeutics Inc.s stock price has bigger growth than BioTime Inc.

Summary

NeuBase Therapeutics Inc. beats on 6 of the 10 factors BioTime Inc.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. Its product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. The company also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products. Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia. BioTime, Inc. was founded in 1990 and is based in Alameda, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Continue reading here:
NeuBase Therapeutics Inc. (NBSE)'s Financial Results Comparing With BioTime Inc. (:) - FinanceMercury